Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Hereditary Breast and Ovarian Cancer Syndrome 1Fanconi Anemia 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Temozolomide 30Radiotherapy 21Etoposide 9Carboplatin 9Bevacizumab 9Cyclophosphamide 8Vincristine 7Radiation 7Filgrastim 7Cisplatin 7Magnetic Resonance Spectroscopy 6Irinotecan 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5etoposide phosphate 4X-Rays 4Specimen Handling 4Phantoms, Imaging 4Lomustine 4Everolimus 4selpercatinib 3larotrectinib 3Thalidomide 3Paclitaxel 3Nuclear Medicine Department, Hospital 3Methotrexate 3Erlotinib Hydrochloride 3Chemotherapy, Adjuvant 3Celecoxib 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Central Nervous System Neoplasms × prexasertib × Clear all
NCT02808650 2023-12-20

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
30 enrolled 16 charts
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡